Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2006 June;72(6) > Minerva Anestesiologica 2006 June;72(6):489-94

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ANESTESIOLOGICA

A Journal on Anesthesiology, Resuscitation, Analgesia and Intensive Care


Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,036


eTOC

 

  SMART 2006 - Milan, May 10-12, 2006


Minerva Anestesiologica 2006 June;72(6):489-94

Copyright © 2006 EDIZIONI MINERVA MEDICA

language: English

Intraoperative use of recombinant activated factor VII (rFVIIa)

De Gasperi A

2nd Division of Anesthesia Intensive Care and Abdominal Organ Transplantation Niguarda Ca’ Granda Hospital, Milan, Italy


FULL TEXT  


Recombinant activated factor VII (rFVIIa, Novoseven®, Novo Nordisk, Denmark) was introduced as a prohemostatic agent in the early 80s: the only indication approved in USA by Food and Drug Administration (FDA) is the spontaneous bleeding in congenital hemophilia patients who developed inhibitors to FVIII and FIX. Recently, EMEA approved the use of rFVIIa in congenital hemophilia patients with inhibitors undergoing surgery, in subjects with congenital FVII deficiency undergoing surgical or invasive procedures, in patients with acquired hemophilia and in case of Glanz­mann’s thromboasthenia. Out of these approved indications, the off label use of rFVIIa is rapidly expanding, particularly in surgical patients with acquired coagulation disorders in order to manage severe, uncontrolled bleeding nonresponsive to conventional therapeutic measures or to reduce blood loss and transfusion requirements in potentially bleeding surgical procedures (major liver surgery, liver transplantation, major abdominal or obstetric surgery, trauma surgery). This paper reviews the more recent data coming from retrospective or prospective studies performed in different surgical settings: so far, the major point to be addressed is the place for rFVIIa as an adjunctive but sometimes lifesaving treatment to control haemostasis and critical bleeding in surgery and critically ill patients.

top of page

Publication History

Cite this article as

Corresponding author e-mail